Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
HAIC-FOLFOXIRI vs Systemic GemOx in Unresectable ICC
NCT03771846Phase 3Unknown
- Sponsor
- Shiming Biotech
- Start
- Aug 2018
- Primary completion
- Aug 2022
- Modality
- DNA Intercalators/Alkylators, Orthosteric Ligands
- Countries
- 1
01
Overview
Phase 3, randomised, open-label trial of irinotecan, oxaliplatin, fluorouracil and folinic acid in intrahepatic cholangiocarcinoma (ICC), sponsored by Shiming Biotech. Status: unknown.
02
Drugs
irinotecanoxaliplatinfluorouracilfolinic acid
03
Conditions
intrahepatic cholangiocarcinoma (ICC)
Beyond the preview
Go deeper on NCT03771846.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03771846.